Skip to main content
Top

03-02-2025 | Vascular Tumor | Original Article

Analysis of prognostic factors and establishment of a recurrence risk prediction model for papillary thyroid carcinoma based on BRAF stratification

Authors: Ang Hu, Yin Li, Zhongyu Wang, Jiahe Tian, Ke Jiang, Jun Chen, Mingjie Jiang, Qiuli Li

Published in: Endocrine

Login to get access

Abstract

Background

Predicting the likelihood of papillary thyroid carcinoma (PTC) recurrence is crucial for improving patient outcomes. The association between the BRAF V600E (BRAF) mutation and PTC recurrence remains controversial. Our goal was to determine prognostic features of PTC patients and construct models for predicting recurrence risk according to BRAF mutation status.

Methods

A total of 811 PTC patients whose clinical information and survival data were available were included in this study. Independent prognostic variables of PTC identified by screening via LASSO-Cox regression analysis were then used to construct nomograms. The performance of the predictive models was assessed according to the C-index, ROC curve, validation curve, and decision curve analyses. Kaplan–Meier curves were used to analyze differences between patients grouped according to prognostic factors and relapse risk.

Results

Multivariate Cox regression analysis demonstrated that extrathyroidal extension (ETE), vascular tumor thrombus, and lymph node yield (LNY) were correlated with recurrence-free survival (RFS) in the BRAF mutation-negative group, while extranodal extension (ENE), number of metastatic lymph node (NMLN), pathological stage, and vascular tumor thrombus were correlated with RFS in the BRAF mutation-positive group. The mutation-stratified predictive models demonstrated better performance than the model without stratification, as indicated by the greater C-index values (0.880 vs. 0.859 vs. 0.753), AUC values (1-year AUC: 0.946 vs. 0.947 vs. 0.758; 3-year AUC: 0.889 vs. 0.871 vs. 0.760; 5-year AUC: 0.845 vs. 0.793 vs. 0.758), and net clinical benefit. The calibration curves at 1 year, 3 years, and 5 years showed good consistency. The bootstrap internal validation had good AUC values exceeding 0.8 and showed a well-fitting calibration curve. Significant differences in RFS were observed between the low-risk and high-risk groups (P < 0.001).

Conclusion

Stratifying patients based on their BRAF mutation status can facilitate the development of better and more targeted postoperative management strategies. Nomograms for BRAF mutation positive and negative patients were developed to precisely and consistently predict recurrence risk in PTC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference A Miranda-Filho, J Lortet-Tieulent, F Bray, B Cao, S Franceschi, S Vaccarella, et al., Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4), 225–234 (2021).CrossRefPubMed A Miranda-Filho, J Lortet-Tieulent, F Bray, B Cao, S Franceschi, S Vaccarella, et al., Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4), 225–234 (2021).CrossRefPubMed
2.
go back to reference C Christofer Juhlin, O Mete, Z.W Baloch, The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr. Relat. Cancer 30(2), e220293 (2023).CrossRefPubMed C Christofer Juhlin, O Mete, Z.W Baloch, The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr. Relat. Cancer 30(2), e220293 (2023).CrossRefPubMed
3.
go back to reference I.D Hay, G.B Thompson, C.S Grant, E.J Bergstralh, C.E Dvorak, C.A Gorman, et al., Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg. 26(8), 879–885 (2002).CrossRefPubMed I.D Hay, G.B Thompson, C.S Grant, E.J Bergstralh, C.E Dvorak, C.A Gorman, et al., Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg. 26(8), 879–885 (2002).CrossRefPubMed
4.
go back to reference B.R Haugen, E.K Alexander, K.C Bible, G.M Doherty, S.J Mandel, Y.E Nikiforov, et al., 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016).CrossRefPubMedPubMedCentral B.R Haugen, E.K Alexander, K.C Bible, G.M Doherty, S.J Mandel, Y.E Nikiforov, et al., 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016).CrossRefPubMedPubMedCentral
5.
go back to reference R.I Haddad, C Nasr, L Bischoff, N.L Busaidy, D Byrd, G Callender, et al., NCCN guidelines insights: thyroid carcinoma, version 2.2018. J. Natl Compr. Canc Netw. 16(12), 1429–1440 (2018).CrossRefPubMed R.I Haddad, C Nasr, L Bischoff, N.L Busaidy, D Byrd, G Callender, et al., NCCN guidelines insights: thyroid carcinoma, version 2.2018. J. Natl Compr. Canc Netw. 16(12), 1429–1440 (2018).CrossRefPubMed
6.
go back to reference M.N Nikiforova, A.I Wald, S Roy, M.B Durso, Y.E Nikiforov, Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J. Clin. Endocrinol. Metab. 98(11), E1852–E1860 (2013).CrossRefPubMedPubMedCentral M.N Nikiforova, A.I Wald, S Roy, M.B Durso, Y.E Nikiforov, Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J. Clin. Endocrinol. Metab. 98(11), E1852–E1860 (2013).CrossRefPubMedPubMedCentral
7.
go back to reference Y.Y Cho, S.Y Park, J.H Shin, Y.L Oh, J.H Choe, J.H Kim, et al., Highly sensitive and specific molecular test for mutations in the diagnosis of thyroid nodules: a prospective study of BRAF-prevalent population. Int. J. Mol. Sci. 21(16), 5629 (2020).CrossRefPubMedPubMedCentral Y.Y Cho, S.Y Park, J.H Shin, Y.L Oh, J.H Choe, J.H Kim, et al., Highly sensitive and specific molecular test for mutations in the diagnosis of thyroid nodules: a prospective study of BRAF-prevalent population. Int. J. Mol. Sci. 21(16), 5629 (2020).CrossRefPubMedPubMedCentral
8.
go back to reference L Jianyong, Z Jinjing, L Zhihui, W Tao, G Rixiang, Z Jingqiang, A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid 28(3), 301–310 (2018).CrossRefPubMed L Jianyong, Z Jinjing, L Zhihui, W Tao, G Rixiang, Z Jingqiang, A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid 28(3), 301–310 (2018).CrossRefPubMed
9.
go back to reference A Subash, P Sinha, A Singh, BRAF mutation and age in differentiated thyroid cancer risk stratification: two sides of the same coin. Oral. Oncol. 106, 104732 (2020).CrossRefPubMed A Subash, P Sinha, A Singh, BRAF mutation and age in differentiated thyroid cancer risk stratification: two sides of the same coin. Oral. Oncol. 106, 104732 (2020).CrossRefPubMed
10.
go back to reference Y Chen, P.M Sadow, H Suh, K.E Lee, J.Y Choi, Y.J Suh, et al., BRAF(V600E) is correlated with recurrence of papillary thyroid microcarcinoma: a systematic review, multi-institutional primary data analysis, and meta-analysis. Thyroid 26(2), 248–255 (2016).CrossRefPubMed Y Chen, P.M Sadow, H Suh, K.E Lee, J.Y Choi, Y.J Suh, et al., BRAF(V600E) is correlated with recurrence of papillary thyroid microcarcinoma: a systematic review, multi-institutional primary data analysis, and meta-analysis. Thyroid 26(2), 248–255 (2016).CrossRefPubMed
11.
go back to reference M Xing, A.S Alzahrani, K.A Carson, Y.K Shong, T.Y Kim, D Viola, et al., Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J. Clin. Oncol. 33(1), 42–50 (2015).CrossRefPubMed M Xing, A.S Alzahrani, K.A Carson, Y.K Shong, T.Y Kim, D Viola, et al., Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J. Clin. Oncol. 33(1), 42–50 (2015).CrossRefPubMed
12.
go back to reference M Yarchoan, V.A LiVolsi, M.S Brose, BRAF mutation and thyroid cancer recurrence. J. Clin. Oncol. 33(1), 7–8 (2015).CrossRefPubMed M Yarchoan, V.A LiVolsi, M.S Brose, BRAF mutation and thyroid cancer recurrence. J. Clin. Oncol. 33(1), 7–8 (2015).CrossRefPubMed
13.
go back to reference C Bal, S Ballal, Is there any true association between BRAF V600E mutation and recurrence, particularly in low-risk, papillary thyroid cancer? J. Clin. Oncol. 33(22), 2481 (2015).CrossRefPubMed C Bal, S Ballal, Is there any true association between BRAF V600E mutation and recurrence, particularly in low-risk, papillary thyroid cancer? J. Clin. Oncol. 33(22), 2481 (2015).CrossRefPubMed
14.
go back to reference C Geng, S Tian, X Gao, X Li, Q Ru, P Zhang, Establishment and validation of a nomogram to predict structural incomplete response in papillary thyroid carcinoma patients: a retrospective study. J. Int. Med. Res. 51(1), 3000605221149880 (2023).CrossRefPubMed C Geng, S Tian, X Gao, X Li, Q Ru, P Zhang, Establishment and validation of a nomogram to predict structural incomplete response in papillary thyroid carcinoma patients: a retrospective study. J. Int. Med. Res. 51(1), 3000605221149880 (2023).CrossRefPubMed
15.
go back to reference H.R Won, M.G Kim, M.S Kim, J.W Chang, B.S Koo, Clinical factors for choosing active surveillance: an analysis of papillary thyroid microcarcinoma patients with recurrence. Eur. Thyroid. J. 12(6), e230195 (2023).CrossRefPubMedPubMedCentral H.R Won, M.G Kim, M.S Kim, J.W Chang, B.S Koo, Clinical factors for choosing active surveillance: an analysis of papillary thyroid microcarcinoma patients with recurrence. Eur. Thyroid. J. 12(6), e230195 (2023).CrossRefPubMedPubMedCentral
16.
go back to reference L Lamartina, G Grani, E Arvat, A Nervo, M.C Zatelli, R Rossi, et al., 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr. Relat. Cancer 25(3), L7–L11 (2018).CrossRefPubMed L Lamartina, G Grani, E Arvat, A Nervo, M.C Zatelli, R Rossi, et al., 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr. Relat. Cancer 25(3), L7–L11 (2018).CrossRefPubMed
17.
go back to reference P Guo, X Wang, L Xia, N Shawureding, Z Hu, Analysis of factors associated with the prognosis of papillary thyroid cancer and the construction of a survival model. Cancer Med. 12(7), 7868–7876 (2023).CrossRefPubMed P Guo, X Wang, L Xia, N Shawureding, Z Hu, Analysis of factors associated with the prognosis of papillary thyroid cancer and the construction of a survival model. Cancer Med. 12(7), 7868–7876 (2023).CrossRefPubMed
18.
go back to reference M.D Bortz, K Kuchta, D.J Winchester, R.A Prinz, T.A Moo-Young, Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer. Surgery 169(1), 2–6 (2021).CrossRefPubMed M.D Bortz, K Kuchta, D.J Winchester, R.A Prinz, T.A Moo-Young, Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer. Surgery 169(1), 2–6 (2021).CrossRefPubMed
19.
go back to reference W.R. Choi, J.L. Roh, G. Gong, K.J. Cho, S.H. Choi, S.Y. Nam et al. Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence. Oral. Oncol. 94, 106–110 (2019)CrossRefPubMed W.R. Choi, J.L. Roh, G. Gong, K.J. Cho, S.H. Choi, S.Y. Nam et al. Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence. Oral. Oncol. 94, 106–110 (2019)CrossRefPubMed
20.
go back to reference T.H. Zhou, B. Lin, F. Wu, K.N. Lu, L.L. Mao, L.Q. Zhao et al. Extranodal extension is an independent prognostic factor in papillary thyroid cancer: a propensity score matching analysis. Front. Endocrinol. 12, 759049 (2021)CrossRef T.H. Zhou, B. Lin, F. Wu, K.N. Lu, L.L. Mao, L.Q. Zhao et al. Extranodal extension is an independent prognostic factor in papillary thyroid cancer: a propensity score matching analysis. Front. Endocrinol. 12, 759049 (2021)CrossRef
21.
go back to reference L Yip, M.N Nikiforova, J.Y Yoo, K.L McCoy, M.T Stang, M.J Armstrong, et al., Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann. Surg. 262(3), 519–525 (2015).CrossRefPubMed L Yip, M.N Nikiforova, J.Y Yoo, K.L McCoy, M.T Stang, M.J Armstrong, et al., Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann. Surg. 262(3), 519–525 (2015).CrossRefPubMed
22.
go back to reference K.W Chung, M.C Chang, D.Y Noh, S.K Oh, K.J Choe, Y.K Youn, RET oncogene expression of papillary thyroid carcinoma in Korea. Surg. Today 34(6), 485–492 (2004).CrossRefPubMed K.W Chung, M.C Chang, D.Y Noh, S.K Oh, K.J Choe, Y.K Youn, RET oncogene expression of papillary thyroid carcinoma in Korea. Surg. Today 34(6), 485–492 (2004).CrossRefPubMed
23.
go back to reference D Pamedytyte, V Simanaviciene, D Dauksiene, E Leipute, A Zvirbliene, V Sarauskas, et al., Association of MicroRNA expression and BRAF(V600E) mutation with recurrence of thyroid cancer. Biomolecules 10(4), 625 (2020).CrossRefPubMedPubMedCentral D Pamedytyte, V Simanaviciene, D Dauksiene, E Leipute, A Zvirbliene, V Sarauskas, et al., Association of MicroRNA expression and BRAF(V600E) mutation with recurrence of thyroid cancer. Biomolecules 10(4), 625 (2020).CrossRefPubMedPubMedCentral
24.
go back to reference P Li, Y Liu, T Wei, X Wang, J Zhu, R Yang, et al., Effect and interactions of BRAF on lymph node metastasis in papillary thyroid carcinoma with hashimoto thyroiditis. J. Clin. Endocrinol. Metab. 109(4), 944–954 (2024).CrossRefPubMed P Li, Y Liu, T Wei, X Wang, J Zhu, R Yang, et al., Effect and interactions of BRAF on lymph node metastasis in papillary thyroid carcinoma with hashimoto thyroiditis. J. Clin. Endocrinol. Metab. 109(4), 944–954 (2024).CrossRefPubMed
25.
go back to reference H Cai, L Zhuge, Z Huang, S Wang, P Shi, D Yan, et al., Distinct risk factors of lateral lymph node metastasis in patients with papillary thyroid cancer based on age stratification. BMC Surg. 24(1), 24 (2024).CrossRefPubMedPubMedCentral H Cai, L Zhuge, Z Huang, S Wang, P Shi, D Yan, et al., Distinct risk factors of lateral lymph node metastasis in patients with papillary thyroid cancer based on age stratification. BMC Surg. 24(1), 24 (2024).CrossRefPubMedPubMedCentral
26.
go back to reference W.X Wu, G.F Qi, J.W Feng, J Ye, L.Z Hong, F Wang, et al., Construction of prediction models for determining the risk of lateral lymph node metastasis in patients with thyroid papillary carcinoma based on gender stratification. Eur. Arch. Otorhinolaryngol. 280(5), 2511–2523 (2023).CrossRefPubMed W.X Wu, G.F Qi, J.W Feng, J Ye, L.Z Hong, F Wang, et al., Construction of prediction models for determining the risk of lateral lymph node metastasis in patients with thyroid papillary carcinoma based on gender stratification. Eur. Arch. Otorhinolaryngol. 280(5), 2511–2523 (2023).CrossRefPubMed
27.
go back to reference M.P Pusztaszeri, J.F Krane, W.C Faquin, BRAF testing and thyroid FNA. Cancer Cytopathol. 123(12), 689–695 (2015).CrossRefPubMed M.P Pusztaszeri, J.F Krane, W.C Faquin, BRAF testing and thyroid FNA. Cancer Cytopathol. 123(12), 689–695 (2015).CrossRefPubMed
28.
go back to reference D.N Poller, S Glaysher, A Agrawal, S Caldera, D Kim, C Yiangou, BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK. J. Clin. Pathol. 67(8), 684–689 (2014).CrossRefPubMed D.N Poller, S Glaysher, A Agrawal, S Caldera, D Kim, C Yiangou, BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK. J. Clin. Pathol. 67(8), 684–689 (2014).CrossRefPubMed
Metadata
Title
Analysis of prognostic factors and establishment of a recurrence risk prediction model for papillary thyroid carcinoma based on BRAF stratification
Authors
Ang Hu
Yin Li
Zhongyu Wang
Jiahe Tian
Ke Jiang
Jun Chen
Mingjie Jiang
Qiuli Li
Publication date
03-02-2025
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-025-04177-z

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more